BioScrip (BIOS) Tops Q3 Views
BioScrip, Inc. (Nasdaq: BIOS) reports Q3 EPS of $0.06, ex-items, 1 cent better than the analyst estimate of $0.05. Revenue for the quarter was $359.4 million, versus the consensus of $356.99 million.
BioScrip, Inc., a specialty pharmaceutical healthcare organization, provides medications and management solutions for chronic and other healthcare conditions in the United States.
Related Categories
EarningsStocks Mentioned
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
